EGFR and neoplasm: Aberrant expression of FOXP3 in ovarian and other epithelial tumors has been implicated in the suppression of antitumor immune responses, thereby promoting tumor immune evasion and contributing to oncogenic pathway activation, including cross-talk with EGFR-mediated signaling cascades [8,9].